NASDAQ$QURE
uniQure NV · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
uniQure reported financial results for the first quarter of 2020 and highlighted recent progress across its business.
uniQure ended the first quarter of 2020 in a position of strength with cash and cash equivalents of $342.0 million. The company reported revenue of $0.1 million and a net loss of $28.0 million, or $0.63 loss per share.
- Completed target patient dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B
- Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting
- Cash and cash equivalents totaled $342.0 million as of March 31, 2020
- The Company currently expects cash and cash equivalents will be sufficient to fund operations into 2022.
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$104K
Forward guidance
uniQure expects to announce new clinical data and advancements from across the business in the second half of the year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro